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ABSTRACT 
Poly lactic-co-glycolic acid (PLGA) based nanoparticles are wildly used for the delivery of bioactive compounds such as 
dexamethasone, curcumin, azithromycin, doxorubicin and indocyanine green. It was found that those polymeric compounds can be 
effectively used for nanoparticle drug delivery. They are more biocompatible and lesser resistant in the case of targeted drug delivery. 
These are observed to have wide-ranging applications. Many of the PLGA polymers are being currently under research for 
commercial use and treatment. They have many fabrication techniques. It is imperative to understand their limitations in the future. 
There is a need for more research to overcome these limitations to develop drugs that are more efficient.  
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INTRODUCTION 
Poly lactic-co-glycolic acid (PLGA) is some of the 
important polymeric compounds that for the fabricate 
devices for the drug delivery.
1
 They have been garnering 
attention in the recent times. It also has application in 
tissue engineering application. The PLGA is a 
compound that is biocompatible and biodegradable. This 
compound has many applications and finds its uses in 
many fields.
2-4
 PLGA is an FDA-approved polymer. In 
particular, PLGA is studied for the development of 
devices that is relevant for the small molecule drugs and 
other macromolecules.
5
 This is observed to have used in 
commercial purposes and research.
6,7
 Many fabrication 
techniques are applied in the devices.
8-10
 These are 
utilizing to understand the factors that affect the 
degradation and drug release of compound.
11-13
 Many of 
these compounds are useful in many operational 
factors.
14-17
 Some of them are detailed in this analysis. In 
the subsequent section, there will be the discussion of 
some of the different kinds of PLGA that is 
commercially used for the treatment of the diseases. 
Cancer – Doxorubicin 
Anthracyclines is observed intercalate with the DNA in 
vitro. This is an essential functionality of the compound 
that finds its application in many sectors. It is observed 
to encompass several crystal structures complexes of the 
DNA. In this case, the Doxorubicin (DOX) breaks the 
DNA and interferes with the DNA synthesis. This 
particular function is imperative for the treatment of the 
compounds. This is the main reason for the compound 
to have pharmacological uses. It is observed that the 
DNA-DOX interaction subsequently leads to the 
poisoning of the topoisomerase II (TOP2A). There is a 
translocation of the DOX into the nucleus and is thought 
to bind with the proteasomes. The TOP2A poison-
mediated cytotoxicity involves itself with the 
mismatching of the repair genes MSH2 and MLH1. 
There is a loss of DNA owing to the mismatch repair 
functions. This results in the resistance of the 
doxorubicin.
18
 Topoisomerase II-DNA is damaged in 
the process, and this ensures the cell death. TP53, a gene, 
is the gene that plays a major role in the apoptosis and 
DNA-damage response. This increases the up-regulation 
of TP53 and is found to impact the anthracycline 
treatment. The ERCC2 and TP53 interact with the p53-
mediated apoptotic pathway with the DOX treatment. 
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The DOX undergoes one-electron reduction and forms a 
DOX-semiquinone radical. These enzymes include the 
mitochondrial NADH dehydrogenase that is present in 
the sarcoplasmic reticulum along with the mitochondria. 
One of the main limitations for this therapeutic 
compound is the toxicity and resistance of the 
compounds. The whole potential of the complex is yet 
to analyze completely.  
Tumor Imaging -- Indocyanine green (ICG) 
Indocyanine green functions as a tricarbocyanine dye 
that is used for diagnose liver function and determine 
the cardiac output and the blood volume of the 
compounds. This ICG compound finds its uses in the 
sentinel lymph node biopsy.
19-22
 It allows the selective 
and minimally invasive access to the regional lymph 
node status along with the malignant tumors. The first 
drain lymph node is known as the “sentinel.” This 
identifies the tumor in the lymph node region. The 
method is then confirmed with the radionuclides. The 
ICG compounds are exploited as it enables in the high 
rate of detection and sensitivity of the compounds in the 
conventional methods. There is a need to achieve high 
rates of deduction and sensitivity in comparison with the 
traditional methods. There is some in vivo experiments 
that showcase the FA-ICG-PLGA-lipid NPs.
23
 They are 
biocompatible and biodegradable in NIR-NPs. These 
have potential uses in the tumor imaging based on the 
high aqueous stability and its fundamental NIR optical 
properties. These are the reasons for considerations. It is 
expected that in the future there will be an increase in 
the tumor imaging process based on the ICG methods.  
Azithromycin – antibacterial 
Azithromycin-loaded poly (lactide-co-glycolide) 
(PLGA) nanoparticles have anti-bacterial properties. 
They impact of the anti-bacterial impacts varied based 
on the drug to polymer ratio. There is also high 
entrapment efficiency. The nanoparticles are prepared 
by nanoprecipitation technique.
24
 The antimicrobial 
activity shows that the nanoparticles were more 
effective than the azithromycin. Clinical activity of the 
azithromycin can be achieved by enhancing nanoparticle 
formulation of the drug. This increases the effective 
therapy when compared to the conventional formulation 
of the azithromycin. There are some clinical trials that 
are being undertaken in the current times to address the 
antibacterial functions of the medicines.  
Curcumin -- Alzheimer's disease 
Curcumin has anti-inflammatory properties. It is 
extracted from the roots of the turmeric plant. These 
have been used in conventional medications for many 
centuries.
25-27
 It is a yellow pigment, and it has a 
polyphenolic molecular structure.
28-30
 Curcumin 
compounds have the potential for the prevention and 
progression of Alzheimer’s.31 This is a multi-functional 
drug. When Tet-1 targeted PLGA was coated with 
curcumin nanoparticles, it observed treat AD with anti-
amyloid property and anti-oxidant property. By tagging 
of the PLGA- curcumin nanoparticle with the Tet-1 
neuropeptide, there was an increase in the efficiency of 
the processes. The preliminary study indicates that there 
is a potential role for Tet-1 neuropeptide in the treatment 
of Alzheimer’s. The impact of the Tet-1 peptide is in the 
neuronal targeting of the Nanoparticles yield positive 
results. Added to this, curcumin has been observed to 
have a biocompatible nature of the curcumin. Owing to 
these factors, this PLGA compound is being studied. 
Apart from this, the curcumin has some positive 
potential impacts in other body conditions. It is because 
of these factors that this compound is being extensively 
studied.  
Dexamethasone -- bone disease 
Dexamethasone is a corticosteroid. It is a natural 
hormone and is utilized for the production of the adrenal 
glands.
32-34
 It is used to replace the chemicals when the 
body does not make enough of such compounds. It is 
also utilized for the alleviation of inflammation, cancer 
treatment and has used in in palliative care.
35-37
 These 
oppositely- charged Poly (D, L-lactic-co-glycolic acid) 
(PLGA) is converted into a colloidal gel and is filled 
with an injectable drug-loaded filler to promote the bond 
defects.
38
 These colloids have been observed to have 
self-assembly and stable 3-D networks. These are then 
molded or extruded based on the share. Once the 
external force was removed, they have a cohesive 
property of the colloidal gel. These are observed to have 
reversibility and shear-thinning behavior. Zero-order 
dexamethasone release was observed in two months. 
These drugs were then encapsulated in PLGA 
nanoparticles, and there was a blending of the drug with 
the colloidal gel. There was a pseudoplastic material 
which showcases that this PLGA colloidal Gel gets 
stimulated and plays an important role in 
osteoconductive bone formation in the cranial bone 
defects of the rat. From this, it can be inferred that 
pseudoplastic, shear-thinning behavior of the colloidal 
gets are expedited for the application of the injectable 
scaffold. This has their uses for the handling of the 
tissue damage and repair. The full potential of the 
Dexamethasone as a PLGA colloidal gel is being 
studied in in-vivo and is yet to be completely analyzed. 
The results have so far been promising.  
SUMMARY 
Poly lactic-co-glycolic acid (PLGA) compounds such as 
Dexamethasone, Curcumin, Azithromycin-loaded poly 
(lactide-co-glycolide) (PLGA) nanoparticles; 
Doxorubicin and Indocyanine Green was analyzed in 
detail in this analysis. It has been determined that these 
polymeric compounds are used for Nanoparticle specific 
drug delivery. These have wide-ranging applications and 
are biocompatible. They are an FDA-approved polymer. 
PLGA compound is utilized for the development of 
devices for the small molecule drugs and in other 
macromolecules. These have applications in commercial 
uses and research. They have many fabrication 
techniques. It is imperative to understand these factors 
that impact the degradation and drug release of the 
compounds. Each one of the elements that has been 
discussed in this analysis has specific uses. The 
complete commercial use and analysis are yet to be done 
on a larger scale. More research needs to be in in-vivo to 
determine the efficacy of these PLGA compounds. 
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